Paare werden als „serodiskordant“ bezeichnet, wenn nur einer von ihnen mit HIV infiziert ist. Normalerweise bleibt es nicht dabei, und dies ist einer der wichtigsten Faktoren der globalen HIV-Epidemie. Dabei lässt sich die Infektion über den Partner heutzutage gut verhindern.
Literatur
Jiwatram-Negron T, El-Bassel N. Systematic Review of Couple-Based HIV Intervention and Prevention Studies: Advantages, Gaps, and Future Directions. AIDS Behav. 2014;18:1864–87
Chemaitelly H, Cremin I, Shelton J et al. Distinct HIV discordancy patterns by epidemic size in stable sexual partnerships in sub-Saharan Africa. Sex Transm Infect. 2012;88:51–7
Chemaitelly H, Shelton JD, Hallett TB, Abu-Raddad LJ. Only a fraction of new HIV infections occur within identifiable stable discordant couples in sub-Saharan Africa. Aids. 2013;27:251–60.
Goodreau SM, Carnegie NB, Vittinghoff E et al. What drives the US and Peruvian HIV epidemics in men who have sex with men (MSM)? PLoS One. 2012;7:e50522
World Health Organization. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. Geneva, Switzerland: September 2015. http://apps.who.int/iris/bitstream/10665/186275/1/9789241509565_eng.pdf
Nelson LJ, Beusenberg M, Habiyambere V et al. Adoption of national recommendations related to use of antiretroviral therapy before and shortly following the launch of the 2013 WHO consolidated guidelines. Aids. 2014;28(Suppl 2):S217–24.
Levi J, Raymond A, Pozniak A et al. Can the UNAIDS 90-90-90 target be achieved? Analysis of 12 national level HIV treatment cascades. 8th IAS Conference on HIV Pathogenesis Treatment and Prevention Vancouver, Canada 18-22 July 2015. http://www.natap.org/2015/IAS/IAS_102.htm
Savasi V, Mandia L, Laoreti A, Cetin I. Reproductive assistance in HIV serodiscordant couples. Hum Reprod Update. 2013;19:136–50.
Sullivan PS, Wall KM, O’Hara B et al. The prevalence of undiagnosed HIV serodiscordance among male couples presenting for HIV testing. Arch Sex Behav. 2014;43:173–80.
Bobashev G, Norton J, Wechsberg W, Toussova O. Are you HIV invincible? A probabilistic study of discordant couples in the context of HIV transmission. PLoS One. 2014;9:e94799.
Kahle EM, Hughes JP, Lingappa JR et al. An empiric risk scoring tool for identifying high-risk heterosexual HIV-1-serodiscordant couples for targeted HIV-1 prevention. J Acquir Immune Defic Syndr. 2013;62:339–47.
Purcell DW, Mizuno Y, Smith DK et al. Incorporating couples-based approaches into HIV prevention for gay and bisexual men: opportunities and challenges. Arch Sex Behav. 2014;43:35–46.
World Health Organization. Prevention and treatment of HIV and other sexually transmitted infections among men who have sex with men and transgender people: recommendations for a public health approach. Geneva, Switzerland: 2011. S. 36. http://apps.who.int/iris/bitstream/10665/44619/1/9789241501750_eng.pdf?ua=1.
Cohen MS, Chen YQ, McCauley M et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493–505.
Baggaley RF, White RG, Hollingsworth TD, Boily MC. Heterosexual HIV-1 infectiousness and antiretroviral use: systematic review of prospective studies of discordant couples. Epidemiology. 2013;24:110–21.
Persson A. ‚The world has changed‘: Pharmaceutical citizenship and the reimagining of serodiscordant sexuality among couples with mixed HIV status in Australia. Sociol Health Illn. 2016;38:380–95
McGowan I. An overview of antiretroviral pre-exposure prophylaxis of HIV infection. Am J Reprod Immunol. 2014;71:624–30.
Molina JM et al. On demand PrEP with oral TDF-FTC in MSM: results of the ANRS Ipergay trial. CROI 2015. 2015 Conference on Retroviruses and Opportunistic Infections (CROI 2015), 23-26 February 2015, Seattle, Washington, USA. Oral late breaker abstract 23LB.
McCormack S et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2016;387:53–60
Gulick R. HPTN 069/ACTG 5305: Phase II Study of Maraviroc-Based Regimens for HIV PrEP in MSM. CROI 2016, Abstract 103
Markowitz M. ÉCLAIR: Phase 2A Safety and PK Study of Cabotegravir LA in HIV-Uninfected Men. CROI 2016, Abstract 106
Whetham J, Taylor S, Charlwood L et al. Pre-exposure prophylaxis for conception (PrEP-C) as a risk reduction strategy in HIV-positive men and HIV-negative women in the UK. AIDS Care. 2014;26:332–6
Author information
Authors and Affiliations
Corresponding author
Additional information
The article is part of a supplement not sponsored by the industry.
Rights and permissions
About this article
Cite this article
Jessen, H. HIV-negative Partner sollen das auch bleiben!. MMW - Fortschritte der Medizin 158 (Suppl 2), 43–46 (2016). https://doi.org/10.1007/s15006-016-8326-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s15006-016-8326-6